Δευτέρα 19 Φεβρουαρίου 2018

US FDA approves durvalumab for unresectable stage III NSCLC

Tthe US Food and Drug Administration (FDA) has approved durvalumab for the treatment of patients with unresectable Stage III non-small cell lung cancer (NSCLC) whose disease has not progressed following concurrent platinum-based chemotherapy and radiation...

from #AlexandrosSfakianakis via Alexandros G.Sfakianakis on Inoreader http://ift.tt/2sGvDGo
via IFTTT

Δεν υπάρχουν σχόλια:

Δημοσίευση σχολίου

Δημοφιλείς αναρτήσεις